<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Oncotarget</journal-id>
      <journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id>
      <journal-id journal-id-type="publisher-id">ImpactJ</journal-id>
      <journal-title-group>
        <journal-title>Oncotarget</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1949-2553</issn>
      <publisher>
        <publisher-name>Impact Journals LLC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26423602</article-id>
      <article-id pub-id-type="pmc">4741824</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Alshami</surname>
            <given-names>Jad</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guiot</surname>
            <given-names>Marie-Christine</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Owen</surname>
            <given-names>Scott</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kavan</surname>
            <given-names>Petr</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gibson</surname>
            <given-names>Neil</given-names>
          </name>
          <xref ref-type="aff" rid="A2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Solca</surname>
            <given-names>Flavio</given-names>
          </name>
          <xref ref-type="aff" rid="A3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cseh</surname>
            <given-names>Agnieszka</given-names>
          </name>
          <xref ref-type="aff" rid="A3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Reardon</surname>
            <given-names>David A.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muanza</surname>
            <given-names>Thierry</given-names>
          </name>
          <xref ref-type="aff" rid="A1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="A5">
            <sup>5</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><sup>1</sup> Clinical Research Unit, Montreal Neurological Institute and Hospital, McGill University Health Center, Montreal, Canada</aff>
      <aff id="A2"><sup>2</sup> Drug Metabolism &amp; Pharmacokinetics, Boehringer Ingelheim Pharma GmbH &amp; Co. KG, Biberach, Germany</aff>
      <aff id="A3"><sup>3</sup> Boehringer Ingelheim RCV GmbH &amp; Co. KG, Vienna, Austria</aff>
      <aff id="A4"><sup>4</sup> Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA</aff>
      <aff id="A5"><sup>5</sup> Radiation Oncology, Jewish General Hospital, Montreal, Canada</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Thierry M. Muanza, <email>thierry.muanza@mcgill.ca</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <day>20</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>21</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <volume>6</volume>
      <issue>32</issue>
      <fpage>34030</fpage>
      <lpage>34037</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>11</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; 2015 Alshami et al.</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>There are few effective treatments for recurrent glioblastoma multiforme (GBM). We present a patient with recurrent GBM who achieved a prolonged response to treatment with afatinib, an irreversible ErbB family blocker, plus temozolomide. A 58-year-old female patient was diagnosed with multifocal primary GBM. After surgical resection, first-line therapy comprised radiotherapy and temozolomide. Following disease progression after 3 temozolomide cycles, the patient entered a phase I/II clinical trial of afatinib (20&#x2013;40 mg daily for 28 days) plus temozolomide (50 mg/m<sup>2</sup> every 21/28 days). Next-generation sequencing analysis of the brain tumor specimen was performed. At the last assessment, 63 treatment cycles had been completed and the patient had survived for ~5 years since recurrence. Significant disease regression was observed after 5 cycles and was maintained during long-term follow-up. Adverse events were consistent with the known tolerability profile of afatinib and were managed by treatment interruption/dose reduction. The patient had several epidermal growth factor receptor <italic>(EGFR)</italic> aberrations, including gene amplification and <italic>EGFRvIII</italic> positivity. Three somatic mutations were identified, including an unprecedented extracellular-domain substitution (D247Y). The patient has survived ~6-fold longer than normally expected in patients with recurrent GBM. The complex <italic>EGFR</italic> genotype may underlie sustained response to afatinib plus temozolomide.</p>
      </abstract>
      <kwd-group>
        <kwd>afatinib</kwd>
        <kwd>temozolomide</kwd>
        <kwd>glioblastoma</kwd>
        <kwd>next-generation sequencing</kwd>
        <kwd>epidermal growth factor receptor</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>INTRODUCTION</title>
      <p>Glioblastoma multiforme (GBM) is the most frequent, highly malignant primary tumor of the central nervous system [<xref rid="R1" ref-type="bibr">1</xref>], accounting for approximately 12&#x2013;15% of all brain tumors [<xref rid="R2" ref-type="bibr">2</xref>]. The current standard of care is temozolomide plus radiotherapy [<xref rid="R3" ref-type="bibr">3</xref>]. However, almost all GBMs recur after first-line therapy and few second-line options have been identified that provide sustained clinical benefit [<xref rid="R4" ref-type="bibr">4</xref>]. Consequently, most patients die soon after tumor recurrence; median overall survival after disease progression is approximately 6&#x2013;9 months [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>]. However, a small proportion of patients can survive for considerably longer [<xref rid="R6" ref-type="bibr">6</xref>].</p>
      <p>As GBM is highly heterogeneous, optimal treatment tailored to the individual is difficult [<xref rid="R5" ref-type="bibr">5</xref>]. Nevertheless, several potential prognostic factors of survival have been identified and include the patient's age, and performance status, tumor location, and extent of surgical resection [<xref rid="R7" ref-type="bibr">7</xref>]. Furthermore, developments in genomic technology have facilitated the identification of molecular markers that could potentially drive treatment decisions. For example, methylation status of the gene encoding O<sup>6</sup>-methylguanine-DNA methyltransferase (MGMT) predicts response to temozolomide-based regimens in elderly patients [<xref rid="R8" ref-type="bibr">8</xref>]. Molecular studies have also identified markers that provide insights into the pathogenesis of GBM and potentially identify rationale for drug targets. For example, heritable genetic aberrations of the ErbB family of receptors, particularly the epidermal growth factor receptor (EGFR), has been implicated in GBM progression [<xref rid="R9" ref-type="bibr">9</xref>]. Overexpression of <italic>EGFR</italic> has been identified in 50&#x2013;60% of GBM cases and is generally thought to confer poor prognosis [<xref rid="R10" ref-type="bibr">10</xref>&#x2013;<xref rid="R12" ref-type="bibr">12</xref>], particularly in the presence of the <italic>EGFRvIII</italic> mutation [<xref rid="R13" ref-type="bibr">13</xref>].</p>
      <p>To date, clinical trials with targeted agents in patients with GBM have been disappointing. For example, bevacizumab and cilengitide have been investigated in a first-line treatment setting, but these studies failed to show improvements in survival [<xref rid="R14" ref-type="bibr">14</xref>&#x2013;<xref rid="R16" ref-type="bibr">16</xref>]. Furthermore, despite the likely role of EGFR in the pathogenesis of disease, reversible EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) do not appear to be effective for recurrent GBM [<xref rid="R17" ref-type="bibr">17</xref>&#x2013;<xref rid="R19" ref-type="bibr">19</xref>]. Recently, a phase I/II study assessed afatinib, a potent irreversible ErbB family blocker, with or without protracted temozolomide, in patients with recurrent GBM [<xref rid="R20" ref-type="bibr">20</xref>]. The rationale for this study was the observation that afatinib inhibits proliferation of cells with <italic>EGFR</italic> mutations that are commonly found in GBM, including <italic>EGFRvIII</italic> and <italic>R108K</italic> [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>]. Furthermore, unlike erlotinib and gefitinib, cytochrome P450 metabolism of afatinib is negligible [<xref rid="R23" ref-type="bibr">23</xref>], thus facilitating combination with chemotherapy or some anti-epileptic drugs. Also, clinical studies have shown afatinib to be effective in several tumor types, notably non-small cell lung cancer including patients with acquired resistance to gefitinib or erlotinib [<xref rid="R24" ref-type="bibr">24</xref>&#x2013;<xref rid="R28" ref-type="bibr">28</xref>]. Unfortunately, the phase I/II study demonstrated that afatinib monotherapy, and afatinib plus temozolomide, had limited activity in unselected patients with recurrent GBM. However, certain selected patient populations (including patients with high levels of EGFR vIII immunoreactivity, <italic>EGFR</italic> amplification, or <italic>PTEN</italic> loss) appeared to have promising response and durable progression-free survival.</p>
      <p>Here, we present a patient with multifocal recurrent GBM who demonstrated a remarkable response to treatment with afatinib plus temozolomide. We undertook broad molecular analysis on this patient's tumor to assess possible mechanistic explanations for the sustained clinical benefit that was observed. Informed consent has been obtained.</p>
    </sec>
    <sec id="s2">
      <title>CASE PRESENTATION</title>
      <p>This right-handed, 58-year-old, previously healthy female patient presented in October 2009 with constant right frontal headache, mild weakness of the left side, gait disturbance, and behavioral changes (anger, forgetfulness).</p>
      <sec id="s2_1">
        <title>Radiological analysis</title>
        <p>Three lesions were identified from radiological assessment (Figure <xref ref-type="fig" rid="F1">1</xref>). These included a right frontal lesion (4.0 &#xD7; 3.7 &#xD7; 4.9 cm) with surrounding edema and mass effect on the adjacent right frontal horn (9 mm to the left of midline); a subcortical left basal frontal area lesion (maximum diameter 1.3 cm) with thick marginal enhancement and central cystic/necrotic appearance, and a left inferior frontal gyrus lesion evident in T2 and Flair images.</p>
        <fig id="F1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <title>Radiological disease assessments relating to first-line treatment (surgical resection and STUPP protocol)</title>
          </caption>
          <graphic xlink:href="oncotarget-06-34030-g001"/>
        </fig>
      </sec>
      <sec id="s2_2">
        <title>Surgical resection</title>
        <p>Subtotal resection of the right frontal lesion was performed in October 2009. Postoperative reduction in tumor size was evident upon radiological assessment (Figure <xref ref-type="fig" rid="F1">1</xref>). The patient was diagnosed with multifocal glioma and pathological findings were consistent with GBM World Health Organization (WHO) grade IV. Tumor MGMT promoter and isocitrate dehydrogenase 1 (IDH1) status were determined to be methylated and wild-type, respectively. Two weeks following surgery, the patient developed a deep vein thrombosis (DVT) in the right lower extremity and a pulmonary embolism. Consequently, the patient was treated with heparin followed by low molecular weight heparin. Within 10 days, she had fully recovered from the DVT.</p>
      </sec>
      <sec id="s2_3">
        <title>Treatments administered</title>
        <p>First-line treatment, initiated in November 2009, comprised the STUPP protocol: radiotherapy (60 Gy over 6 weeks; intensity modulated radiotherapy [IMRT]) with concurrent oral temozolomide (75 mg/m<sup>2</sup> daily for 42 days), followed by adjuvant temozolomide 150&#x2013;200 mg/m<sup>2</sup> every 5/28 days [<xref rid="R29" ref-type="bibr">29</xref>]. The patient tolerated the concurrent treatment well. However, in February 2010, disease progression was observed by magnetic resonance imaging (MRI) after 3 cycles of adjuvant temozolomide (increase in left frontal lesion with mass effect; Figure <xref ref-type="fig" rid="F1">1</xref>).</p>
        <p>Second-line treatment, initiated in April 2010, was determined according to participation in a clinical trial of afatinib with or without daily temozolomide. The patient was randomized to the combined afatinib (20&#x2013;40 mg daily for 28 days) and temozolomide (50 mg/m<sup>2</sup> orally [p.o.] every 21/28 days) arm. After 1 cycle of second-line treatment, MRI revealed minimal decrease in lesion size. After 5 cycles, significant disease regression was observed and maintained in subsequent assessments to 54 months (Figure <xref ref-type="fig" rid="F2">2</xref>). A full spine MRI performed in November 2014 showed no evidence of metastases in the cervical, thoracic or lumbar regions and the most recent MRI (January 2015) showed stable disease. At the time of writing (April 2015), the patient had completed 63 cycles and treatment was ongoing.</p>
        <fig id="F2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <title>Radiological disease assessments relating to second-line treatment (afatinib and temozolomide)</title>
          </caption>
          <graphic xlink:href="oncotarget-06-34030-g002"/>
        </fig>
      </sec>
      <sec id="s2_4">
        <title>Adverse events</title>
        <p>In total, the patient experienced four incidences of grade III adverse events that were considered to be at least probably related to second-line treatment: one incidence of maculopapular rash and three incidences of paronychia. The maculopapular rash occurred during the third cycle and was managed with a 2-week interruption of treatment followed by a dose reduction (afatinib from 40 to 30 mg p.o. daily; temozolomide from 140 to 90 mg p.o. daily). Grade III paronychia occurred during cycle 16, cycle 20 (leading to a dose reduction of afatinib from 30 to 20 mg p.o. daily), and cycle 36 (leading to a treatment interruption of 7 weeks). Dose reductions led to marked improvement in symptoms.</p>
        <p>Other drug-related adverse events included grade I nausea and vomiting (cycle 1; managed with anti-emetics), grade II diarrhea (cycle 1; managed with loperamide), grade I rash (cycles 1 and 2; managed with hydrocortisone cream), weight loss, and fatigue.</p>
        <p>The patient's neurologic and physical status were stable (Karnofsky Performance Status &gt; 90) throughout second-line treatment.</p>
      </sec>
      <sec id="s2_5">
        <title>Molecular analysis</title>
        <p>DNA was isolated from a brain tumor specimen from the primary resection and subjected to FoundationOne&#x2122; next-generation sequencing [<xref rid="R30" ref-type="bibr">30</xref>]. The entire coding sequence of 236 cancer-related genes, plus 47 introns from 19 genes often rearranged or altered in cancer, was assessed. Fifteen cancer-related gene alterations were evident.</p>
        <p>A number of <italic>EGFR</italic> aberrations were observed (Table <xref ref-type="table" rid="T1">1</xref>). The patient was positive for <italic>EGFR</italic> amplification (estimated copy number of 60) and was likely positive for the <italic>EGFRvIII</italic> mutation (the extent of the <italic>EGFRvIII</italic> variant is difficult to quantify with next-generation sequencing). It is not unusual to observe amplification of both wild-type <italic>EGFR</italic> and <italic>EGFRvIII</italic> in the same tumor; <italic>EGFRvIII</italic> is rarely observed in isolation [<xref rid="R31" ref-type="bibr">31</xref>]. Two subclonal somatic mutations were observed (2% of reads), P596L and G598V. Both of these mutations have previously been identified in patients with GBM [<xref rid="R21" ref-type="bibr">21</xref>]. Interestingly, an additional unprecedented variant of unknown significance was observed in the extracellular domain of EGFR (D247Y; 89% of reads). This could potentially be a rare single nucleotide polymorphism (SNP), but could also be a somatically acquired allele that may possibly be linked to the observed clinical response to afatinib.</p>
        <table-wrap id="T1" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <title>Details of gene alterations detected in 15 genes</title>
          </caption>
          <table frame="box" rules="all">
            <thead>
              <tr>
                <th align="left" valign="middle" rowspan="1" colspan="1">Number</th>
                <th align="center" valign="middle" rowspan="1" colspan="1">Gene</th>
                <th align="center" valign="middle" rowspan="1" colspan="1">Description</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">1</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>EGFR</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Amplification of full gene, estimated gene copy number = 60</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">2</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>EGFR</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Known somatic mutation P596L (c.1787C &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">3</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>EGFR</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Known somatic mutation G598V (c.1793G &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>EGFR</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Known somatic mutation <italic>EGFRvIII</italic></td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">5</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>EGFR</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance D247Y (c.739G &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">6</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>PTEN</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Known somatic mutation R130* (c.388C &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">7</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>CDKN2A (p16)</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Homozygous deletion of full gene</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>CDKN2B (p15)</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Homozygous deletion of full gene</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">9</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>BAP1</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance V447I (c.1339G &gt; A)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">10</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>BCORL1</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance T1111M (c.3332C &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">11</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>C17orf39</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance N285Y (c.853A &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">12</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>CDH1</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance P30T (c.88C &gt; A)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">13</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>EPHA5</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance M987T (c.2960T &gt; C)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">14</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>ESR1</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance H6Y (c.16C &gt; T)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">15</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>GRIN2A</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance C800 (c.2400C &gt; A)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">16</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>MAP3K1</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance S939C (c.2816C &gt; G)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">17</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>NOTCH3</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance R1669H (c.5006G &gt; A)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">18</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>STAG2</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Variant of unknown significance splice (c.2026&#x2013;1G &gt; C)</td>
              </tr>
              <tr>
                <td align="left" valign="middle" rowspan="1" colspan="1">19</td>
                <td align="left" valign="middle" rowspan="1" colspan="1">
                  <bold>
                    <italic>IKZF1</italic>
                  </bold>
                </td>
                <td align="left" valign="middle" rowspan="1" colspan="1">Amplification of full gene, estimated gene copy number = 51</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>A: adenine; C: cytosine; EGFR: epidermal growth factor receptor; G: guanine; GBM: glioblastoma; SNP: single nucleotide polymorphism; T: thymine.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>Other genetic aberrations of interest included a null mutation in <italic>PTEN</italic> and deletion of <italic>CDKN2A</italic> and <italic>B</italic>, all of which are common genetic features of GBM. A number of other genes were found to have single base-pair changes, including <italic>BAP1</italic>, <italic>BCORL1</italic>, <italic>C170rf39</italic>, <italic>CDH1</italic>, <italic>EPHA5</italic>, <italic>ESR1</italic>, <italic>GRIN2A</italic>, and <italic>MAP3K1</italic>. It is likely that all of these aberrations represent rare heterozygous SNPs without any functional relevance (Table <xref ref-type="table" rid="T1">1</xref>). Of note, several other common molecular genetic features of GBM, such as mutations in <italic>TP53</italic>, <italic>NF1</italic>, and <italic>IDH1</italic>, were absent in this patient. In independent analysis, the <italic>MGMT</italic> promoter was found to be methylated.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>AFATINIB IN MOUSE XENOGRAFT MODELS OF GBM</title>
      <p>The anti-tumor activity of afatinib has been evaluated in two different glioblastoma models derived from adult patients. These experiments were performed before trial initiation with the aim of illustrating that afatinib could have single-agent activity in glioblastoma models. Of note, both models have some degree of genetic similarity with the tumor profile of the patient described in this report (likely positive for <italic>EGFRvIII mutation</italic> and positive for EGFR amplification). The GB218 glioblastoma model is characterized by the presence of <italic>EGFRvIII</italic> mutation. In this model, monotherapy treatment (44 days) with afatinib (10, 7.5 or 5mg/kg/day) or erlotinib (50mg/kg/day) resulted in tumor growth inhibition (TGI) of 60.0, 69.3, 46.9, and 52.2%, respectively (Figure <xref ref-type="fig" rid="F3">3A</xref>). These doses are below the usual maximum tolerated doses in mice. GB218 also displayed sensitivity to temozolomide (50 or 25 mg/kg/day) resulting in complete suppression of tumor growth (TGI = 103.4%). The GB138 glioblastoma model is characterized by <italic>EGFR</italic> gene copy number gain (EGFR amplification). In this model, monotherapy treatment (28 days) with afatinib (10 or 7.5 mg/kg/day) or erlotinib (40mg/kg/day) resulted in TGI of 91.5, 81.8 and 72.7%, respectively (Figure <xref ref-type="fig" rid="F3">3B</xref>). Temozolomide (25 mg/kg/5 days on - 2 days off) resulted in complete suppression of tumor growth (TGI = 110.5%).</p>
      <fig id="F3" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <title>Effect of afatinib, erlotinib and temozolomide in two different human patient-derived xenograft models of glioblastoma</title>
          <p><bold>A.</bold> GB218 tumor growth kinetics. Groups of GB218 tumor-bearing mice (<italic>n</italic> = 7/group) were treated orally in weekly schedules either with afatinib 10, 7.5 or 5 mg/kg/day, erlotinib 50 mg/kg/day, temozolomide 25 or 50 mg/kg/5 days, or with the vehicle only. Median tumor volumes are plotted over time. Day 1 was the first and Day 44 the final day of treatment. <bold>B.</bold> GB138 tumor growth kinetics. Groups of GB138 tumor-bearing mice (<italic>n</italic> = 7/group) were treated orally in weekly schedules either with afatinib 10 or 7.5 mg/kg/day, erlotinib 40 mg/kg/day, temozolomide 25 mg/kg/5 days, or with the vehicle only. Median tumor volumes are plotted over time. Day 1 was the first and Day 28 the final day of treatment.</p>
        </caption>
        <graphic xlink:href="oncotarget-06-34030-g003"/>
      </fig>
    </sec>
    <sec id="s4">
      <title>DISCUSSION</title>
      <p>This case report describes a sustained clinical and radiographic response in a patient with recurrent multifocal GBM. Since progression on first-line therapy, the patient has survived for 60 months, approximately 6 times longer than the median overall survival generally observed in patients with recurrent GBM. It is not possible to say with certainty that these striking observations are solely attributable to treatment with afatinib and temozolomide. Moreover, pseudo-progression cannot be definitively excluded because the tumor is <italic>MGMT</italic>-methylated and disease progression was observed only 4 months after chemoradiation treatment.</p>
      <p>This patient was participating in a clinical trial of afatinib with or without temozolomide for recurrent GBM (NCT00727506) [<xref rid="R20" ref-type="bibr">20</xref>]. The main finding of this study was that afatinib has limited effect on survival in unselected patients. Overall, median progression-free survival in patients treated with afatinib plus temozolomide (<italic>n</italic> = 39) was 1.5 months versus 1.9 months in patients treated with temozolomide only (<italic>n</italic> = 39). Nevertheless, subanalysis suggested that patients with certain molecular characteristics may benefit from combination therapy versus temozolomide monotherapy. For example, median progression-free survival was 2.7 versus 1.0 months in patients with <italic>EGFR</italic> amplification, and 2.7 versus 1.9 months in patients with <italic>PTEN</italic> loss. The present patient exhibited characteristics associated with a stronger afatinib response: <italic>EGFR</italic> amplification, <italic>EGFRvIII</italic> positivity, and a null mutation in <italic>PTEN</italic>. Our preclinical data in mouse xenograft models demonstrate that tumors with these EGFR aberrations are sensitive to tyrosine kinase inhibitors.</p>
      <p>We have undertaken broad molecular analysis of the patient to try to more clearly define the molecular aberrations that could potentially identify patients who might achieve significant clinical benefit from afatinib plus temozolomide. The patient's overall molecular pathology was largely consistent with the &#x2018;classical GBM&#x2019; subtype proposed by Verhaak, et al. [<xref rid="R32" ref-type="bibr">32</xref>], which is characterized by <italic>EGFR</italic> amplification and a lack of abnormalities in <italic>TP53</italic>, <italic>NF1</italic>, <italic>PDGFR&#x3B1;</italic>, and <italic>IDH1</italic>. It is possible that EGFR amplification and <italic>EGFRvIII</italic> positivity could underlie the encouraging response to afatinib plus temozolomide. However, 3 additional <italic>EGFR</italic> aberrations were also identified. Two of these aberrations, P596L and G598V, were clonally rare within the tumor and are therefore unlikely candidates for driving response to combination therapy. However, the third aberration, D247Y, appeared to be clonally amplified in the tumor and could therefore conceivably contribute to the observed response to afatinib plus temozolomide. Interestingly, this aberration affects the extracellular domain of EGFR. A previous study has shown that variants in the extracellular domain are relatively common in patients with GBM (13.6%) and confer sensitivity to EGFR tyrosine kinase inhibitors [<xref rid="R21" ref-type="bibr">21</xref>]. Based on these observations, we hypothesize that the complex <italic>EGFR</italic> genotype comprising extracellular aberrations in concert with focal amplification and the <italic>EGFRvIII</italic> mutation may underlie the observed sensitivity to afatinib and temozolomide. This hypothesis may be tested further in a suitable <italic>in vitro</italic> model. Moreover, it would be interesting to assess patients who have been treated with the combination in the phase I/II trial for <italic>EGFR</italic> extracellular aberrations. It is important to note that the tumor specimen sequenced was from initial resection, prior to any treatment; as such, the profile may have evolved upon exposure to subsequent therapies, but we cannot speculate on the nature of any treatment-driven evolution.</p>
      <p>Adverse events in this case were manageable and in line with previous studies of the safety profiles of afatinib and temozolomide, including the GBM trial [<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R33" ref-type="bibr">33</xref>]. In relation to safety, the GBM study also reported a lack of pharmacokinetic interactions between afatinib and temozolomide [<xref rid="R20" ref-type="bibr">20</xref>], supporting a strategy of co-administration of these drugs.</p>
      <p>In conclusion, we describe a novel extracellular <italic>EGFR</italic> mutation in a recurrent GBM patient who demonstrated uncharacteristically prolonged survival following afatinib plus daily temozolomide. Studies to confirm the criteria for predicting afatinib response, and to determine the optimal dosing regimen, are awaited with interest.</p>
      <sec id="s4_1">
        <title>Ethics statement</title>
        <p>Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki and according to national and international guidelines and has been approved by the authors&#x2019; institutional review board.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGMENTS AND FUNDING</title>
      <p>The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Lynn Pritchard, of GeoMed, an Ashfield company, part of UDG Healthcare plc, during the preparation of this article. This study was supported by Boehringer Ingelheim.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>
          <bold>CONFLICTS OF INTEREST</bold>
        </p>
        <p>David A. Reardon has received consultancy fees for Merck, Roche/Genentech, Novartis, Stemline and Amgen, and speaking fees for Merck and Roche/Genentech. Neil Gibson, Flavio Solca, Agnieszka Cseh are employees of Boehringer Ingelheim. For the remaining authors none were declared.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Llaguno</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>McKay</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Parada</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models</article-title>
          <source>BMB Rep</source>
          <year>2011</year>
          <volume>44</volume>
          <fpage>158</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="pmid">21429292</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kleihues</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Burger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <chapter-title>Glioblastoma</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Kleihues</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cavenee</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <source>Pathology and genetics of tumours of the nervous system</source>
          <publisher-loc>Lyon</publisher-loc>
          <publisher-name>IARC Press</publisher-name>
          <year>2000</year>
          <fpage>29</fpage>
          <lpage>39</lpage>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilbert</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aldape</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Stupp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hegi</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Jaeckle</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Wefel</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Won</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blumenthal</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Mahajan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Erridge</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial</article-title>
          <source>J Clin Oncol</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>4085</fpage>
          <lpage>4091</lpage>
          <pub-id pub-id-type="pmid">24101040</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cloughesy</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Wick</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Standards of care for treatment of recurrent glioblastoma&#x2014;are we there yet?</article-title>
          <source>Neuro Oncol</source>
          <year>2013</year>
          <volume>15</volume>
          <fpage>4</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">23136223</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chaudhry</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Ferraro</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Snelling</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Bregy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Madhavan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Komotar</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century</article-title>
          <source>Cancer Invest</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>287</fpage>
          <lpage>308</lpage>
          <pub-id pub-id-type="pmid">23614654</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krex</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Klink</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hartmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>von Deimling</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pietsch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sabel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Steinbach</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Heese</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Reifenberger</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Weller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schackert</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival with glioblastoma multiforme</article-title>
          <source>Brain</source>
          <year>2007</year>
          <volume>130</volume>
          <fpage>2596</fpage>
          <lpage>2606</lpage>
          <pub-id pub-id-type="pmid">17785346</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazaris</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Altshuler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Poisson</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mikkelsen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Rosenblum</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kalkanis</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Key determinants of short-term and long-term glioblastoma survival: a 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital</article-title>
          <source>Clin Neurol Neurosurg</source>
          <year>2014</year>
          <volume>120</volume>
          <fpage>103</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="pmid">24731587</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kreth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kreth</surname>
              <given-names>FW</given-names>
            </name>
          </person-group>
          <article-title>Personalized treatment strategies in glioblastoma: MGMT promoter methylation status</article-title>
          <source>Onco Targets Ther</source>
          <year>2013</year>
          <volume>6</volume>
          <fpage>1363</fpage>
          <lpage>1372</lpage>
          <pub-id pub-id-type="pmid">24109190</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersson</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schwartzbaum</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wiklund</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Sjostrom</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tsavachidis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ahlbom</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Auvinen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Collatz-Laier</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Feychting</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Johansen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kiuru</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lonn</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk</article-title>
          <source>Acta Oncol</source>
          <year>2010</year>
          <volume>49</volume>
          <fpage>767</fpage>
          <lpage>775</lpage>
          <pub-id pub-id-type="pmid">20446891</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frederick</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>XY</given-names>
            </name>
            <name>
              <surname>Eley</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas</article-title>
          <source>Cancer Res</source>
          <year>2000</year>
          <volume>60</volume>
          <fpage>1383</fpage>
          <lpage>1387</lpage>
          <pub-id pub-id-type="pmid">10728703</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Etienne</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Formento</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Lebrun-Frenay</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gioanni</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chatel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Paquis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bernard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Courdi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bensadoun</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Pignol</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Francoual</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grellier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Frenay</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome</article-title>
          <source>Clin Cancer Res</source>
          <year>1998</year>
          <volume>4</volume>
          <fpage>2383</fpage>
          <lpage>2390</lpage>
          <pub-id pub-id-type="pmid">9796969</pub-id>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pelloski</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Ballman</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Furth</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sulman</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Bhat</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Yung</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Colman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Heimberger</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Suki</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>2288</fpage>
          <lpage>2294</lpage>
          <pub-id pub-id-type="pmid">17538175</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shinojima</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shiraishi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kamiryo</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kochi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Makino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saya</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kuratsu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Oka</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishimaru</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ushio</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme</article-title>
          <source>Cancer Res</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>6962</fpage>
          <lpage>6970</lpage>
          <pub-id pub-id-type="pmid">14583498</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chinot</surname>
              <given-names>OL</given-names>
            </name>
            <name>
              <surname>Wick</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Henriksson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Saran</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nishikawa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Carpentier</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Hoang-Xuan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kavan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cernea</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brandes</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Hilton</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Abrey</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <fpage>709</fpage>
          <lpage>722</lpage>
          <pub-id pub-id-type="pmid">24552318</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilbert</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Dignam</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Wefel</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Blumenthal</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Vogelbaum</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Colman</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Chakravarti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pugh</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Won</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jeraj</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Jaeckle</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A randomized trial of bevacizumab for newly diagnosed glioblastoma</article-title>
          <source>N Engl J Med</source>
          <year>2014</year>
          <volume>370</volume>
          <fpage>699</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="pmid">24552317</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stupp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hegi</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Gorlia</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Erridge</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Grujicic</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Steinbach</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Wick</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Tarnawski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Nam</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Weyerbrock</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hau</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Taphoorn</surname>
              <given-names>MJB</given-names>
            </name>
            <name>
              <surname>Nabors</surname>
              <given-names>LB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study</article-title>
          <source>J Clin Oncol</source>
          <year>2013</year>
          <volume>31</volume>
          <comment>LBA2009</comment>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franceschi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lonardi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Magrini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tosoni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grosso</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Scopece</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Blatt</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Urbini</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pession</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tallini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Crino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bres</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)</article-title>
          <source>Br J Cancer</source>
          <year>2007</year>
          <volume>96</volume>
          <fpage>1047</fpage>
          <lpage>1051</lpage>
          <pub-id pub-id-type="pmid">17353924</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norden</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Raizer</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Abrey</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Lamborn</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Lassman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Yung</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Gilbert</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Fine</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Deangelis</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Cloughesy</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Robins</surname>
              <given-names>HI</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma</article-title>
          <source>J Neurooncol</source>
          <year>2010</year>
          <volume>96</volume>
          <fpage>211</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="pmid">19562255</pub-id>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reardon</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Desjardins</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Vredenburgh</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Gururangan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Herndon</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Marcello</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Norfleet</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>McLendon</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Sampson</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>HS</given-names>
            </name>
          </person-group>
          <article-title>Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma</article-title>
          <source>J Neurooncol</source>
          <year>2010</year>
          <volume>96</volume>
          <fpage>219</fpage>
          <lpage>230</lpage>
          <pub-id pub-id-type="pmid">19562254</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reardon</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Nabors</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Perry</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kavan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mathieu</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Phuphanich</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cseh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wind</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Eisenstat</surname>
              <given-names>DD</given-names>
            </name>
          </person-group>
          <article-title>Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma</article-title>
          <source>Neuro Oncol</source>
          <year>2014</year>
          <volume>17</volume>
          <fpage>430</fpage>
          <lpage>439</lpage>
          <pub-id pub-id-type="pmid">25140039</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Vivanco</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Beroukhim</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>WL</given-names>
            </name>
            <name>
              <surname>DeBiasi</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Yoshimoto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Nghiemphu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yuza</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Greulich</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>RK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain</article-title>
          <source>PLoS Med</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>e485</fpage>
          <pub-id pub-id-type="pmid">17177598</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ambrogio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shimamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chirieac</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Padera</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Shapiro</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Baum</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Himmelsbach</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rettig</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Meyerson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Solca</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</article-title>
          <source>Oncogene</source>
          <year>2008</year>
          <volume>27</volume>
          <fpage>4702</fpage>
          <lpage>4711</lpage>
          <pub-id pub-id-type="pmid">18408761</pub-id>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stopfer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Marzin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Narjes</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gansser</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Shahidi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Uttereuther-Fischer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ebner</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers</article-title>
          <source>Cancer Chemother Pharmacol</source>
          <year>2012</year>
          <volume>69</volume>
          <fpage>1051</fpage>
          <lpage>1061</lpage>
          <pub-id pub-id-type="pmid">22200729</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Cadranel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>YM</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Heo</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Crino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>EH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</article-title>
          <source>Lancet Oncol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>528</fpage>
          <lpage>538</lpage>
          <pub-id pub-id-type="pmid">22452896</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>YL</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Massey</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial</article-title>
          <source>Lancet Oncol</source>
          <year>2014</year>
          <volume>15</volume>
          <fpage>213</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="pmid">24439929</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Shih</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Hsia</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Ou</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Sequist</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Dudek</surname>
              <given-names>AZ</given-names>
            </name>
            <name>
              <surname>Shahidi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cong</surname>
              <given-names>XJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial</article-title>
          <source>Lancet Oncol</source>
          <year>2012</year>
          <volume>13</volume>
          <fpage>539</fpage>
          <lpage>548</lpage>
          <pub-id pub-id-type="pmid">22452895</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sequist</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>O'Byrne</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hirsh</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mok</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Geater</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Orlov</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tsai</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Boyer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Bennouna</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations</article-title>
          <source>J Clin Oncol</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>3327</fpage>
          <lpage>3334</lpage>
          <pub-id pub-id-type="pmid">23816960</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katakami</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Atagi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goto</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Horai</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ichinose</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Koboyashi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takeda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kiura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nishio</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Seki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ebisawa</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</article-title>
          <source>J Clin Oncol</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>3335</fpage>
          <lpage>3341</lpage>
          <pub-id pub-id-type="pmid">23816963</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stupp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mason</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>van den Bent</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Weller</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Taphoorn</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Belanger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brandes</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Marosi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bogdahn</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Curschmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Janzer</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Ludwin</surname>
              <given-names>SK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title>
          <source>N Engl.J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <fpage>987</fpage>
          <lpage>996</lpage>
          <pub-id pub-id-type="pmid">15758009</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frampton</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Fichtenholtz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Downing</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schnall-Levin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sanford</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>An</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Juhn</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brennan</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title>
          <source>Nat Biotechnol</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>1023</fpage>
          <lpage>1031</lpage>
          <pub-id pub-id-type="pmid">24142049</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zadeh</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bhat</surname>
              <given-names>KP</given-names>
            </name>
            <name>
              <surname>Aldape</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>EGFR and EGFRvIII in glioblastoma: partners in crime</article-title>
          <source>Cancer Cell</source>
          <year>2013</year>
          <volume>24</volume>
          <fpage>403</fpage>
          <lpage>404</lpage>
          <pub-id pub-id-type="pmid">24135276</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verhaak</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Hoadley</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Purdom</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Qi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wilkerson</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Golub</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mesirov</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Alexe</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lawrence</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>O'Kelly</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1</article-title>
          <source>Cancer Cell</source>
          <year>2010</year>
          <volume>17</volume>
          <fpage>98</fpage>
          <lpage>110</lpage>
          <pub-id pub-id-type="pmid">20129251</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brandes</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Tosoni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cavallo</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bertorelle</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gioia</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Franceschi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Biscuola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blatt</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Crino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ermani</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)</article-title>
          <source>Br J Cancer</source>
          <year>2006</year>
          <volume>95</volume>
          <fpage>1155</fpage>
          <lpage>1160</lpage>
          <pub-id pub-id-type="pmid">17024124</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
